NL8502178A - Nieuwe farmaceutische preparaten. - Google Patents
Nieuwe farmaceutische preparaten. Download PDFInfo
- Publication number
- NL8502178A NL8502178A NL8502178A NL8502178A NL8502178A NL 8502178 A NL8502178 A NL 8502178A NL 8502178 A NL8502178 A NL 8502178A NL 8502178 A NL8502178 A NL 8502178A NL 8502178 A NL8502178 A NL 8502178A
- Authority
- NL
- Netherlands
- Prior art keywords
- theophylline
- ketotifene
- asthma
- free
- pharmaceutical composition
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 211
- 229960000278 theophylline Drugs 0.000 claims description 105
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 64
- 208000006673 asthma Diseases 0.000 claims description 44
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 22
- 239000008188 pellet Substances 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 230000003449 preventive effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 229940075420 xanthine Drugs 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000011321 prophylaxis Methods 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- 239000011162 core material Substances 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 230000001976 improved effect Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 208000000884 Airway Obstruction Diseases 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000011149 active material Substances 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 19
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 15
- 108010003541 Platelet Activating Factor Proteins 0.000 description 15
- 229940124630 bronchodilator Drugs 0.000 description 14
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 10
- 229960003556 aminophylline Drugs 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000009044 synergistic interaction Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000001088 anti-asthma Effects 0.000 description 6
- 239000000924 antiasthmatic agent Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010006482 Bronchospasm Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000014181 Bronchial disease Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007883 bronchodilation Effects 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000035874 hyperreactivity Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000003874 central nervous system depressant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XYBFIZMXHHNHKG-UHFFFAOYSA-N 1,3-dimethyl-7h-purine-2,6-dione;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.O=C1N(C)C(=O)N(C)C2=C1NC=N2 XYBFIZMXHHNHKG-UHFFFAOYSA-N 0.000 description 1
- QFJDTNNSYMKICD-UHFFFAOYSA-N 1-aminopropan-2-ol;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)CN.O=C1N(C)C(=O)N(C)C2=C1NC=N2 QFJDTNNSYMKICD-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000033399 Anaphylactic responses Diseases 0.000 description 1
- 206010006440 Bronchial obstruction Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920004449 Halon® Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000001813 broncholytic effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- HBGYWKVYHHULPL-UHFFFAOYSA-L calcium;1,3-dimethyl-7h-purine-2,6-dione;2-oxidobenzoate Chemical compound [Ca+2].[O-]C(=O)C1=CC=CC=C1[O-].O=C1N(C)C(=O)N(C)C2=C1NC=N2 HBGYWKVYHHULPL-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- -1 mentioned above Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000479 mixture part Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH392784 | 1984-08-16 | ||
| CH392784 | 1984-08-16 | ||
| CH438784 | 1984-09-14 | ||
| CH438784 | 1984-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8502178A true NL8502178A (nl) | 1986-03-17 |
Family
ID=25694194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8502178A NL8502178A (nl) | 1984-08-16 | 1985-08-02 | Nieuwe farmaceutische preparaten. |
Country Status (15)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU202753B (en) * | 1986-06-21 | 1991-04-29 | Sandoz Ag | Process for producing retard pharmaceutical compositions containing cetotiphene |
| GB2284761A (en) * | 1993-12-03 | 1995-06-21 | Euro Celtique Sa | Prophylactic treatment of asthma |
| US8282955B2 (en) | 2001-10-15 | 2012-10-09 | Ferring B.V. | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease |
| US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| WO2004093883A2 (en) | 2003-04-23 | 2004-11-04 | Ferring B.V. | Sachet for a pharmaceutical composition |
| EP1547601A1 (en) * | 2003-12-23 | 2005-06-29 | Ferring B.V. | Coating method |
| CN106913572B (zh) * | 2017-04-06 | 2019-09-20 | 地奥集团成都药业股份有限公司 | 一种复方茶酮缓释片及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51142543A (en) * | 1975-05-20 | 1976-12-08 | Sandoz Ag | Improvement in organic compound |
-
1985
- 1985-08-02 IT IT48441/85A patent/IT1200102B/it active
- 1985-08-02 NL NL8502178A patent/NL8502178A/nl not_active Application Discontinuation
- 1985-08-02 HU HU852971A patent/HUT40568A/hu unknown
- 1985-08-06 WO PCT/CH1985/000120 patent/WO1986001108A1/de unknown
- 1985-08-08 DE DE19853528481 patent/DE3528481A1/de not_active Withdrawn
- 1985-08-12 SE SE8503771A patent/SE8503771L/xx not_active Application Discontinuation
- 1985-08-12 GB GB08520189A patent/GB2163957A/en not_active Withdrawn
- 1985-08-14 GR GR851988A patent/GR851988B/el unknown
- 1985-08-14 BE BE1/011316A patent/BE903065A/fr not_active IP Right Cessation
- 1985-08-14 FR FR8512368A patent/FR2569109A1/fr not_active Withdrawn
- 1985-08-14 AU AU46171/85A patent/AU4617185A/en not_active Abandoned
- 1985-08-14 IL IL76089A patent/IL76089A0/xx unknown
- 1985-08-14 DK DK370085A patent/DK370085A/da not_active Application Discontinuation
- 1985-08-14 PT PT80961A patent/PT80961B/pt unknown
- 1985-08-16 LU LU86044A patent/LU86044A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1986001108A1 (fr) | 1986-02-27 |
| IT8548441A0 (it) | 1985-08-02 |
| LU86044A1 (fr) | 1986-02-18 |
| IT1200102B (it) | 1989-01-05 |
| DK370085D0 (da) | 1985-08-14 |
| GB8520189D0 (en) | 1985-09-18 |
| DE3528481A1 (de) | 1986-02-27 |
| SE8503771L (sv) | 1986-02-17 |
| FR2569109A1 (fr) | 1986-02-21 |
| GB2163957A (en) | 1986-03-12 |
| HUT40568A (en) | 1987-01-28 |
| IL76089A0 (en) | 1985-12-31 |
| DK370085A (da) | 1986-02-17 |
| AU4617185A (en) | 1986-02-20 |
| PT80961B (en) | 1987-07-13 |
| PT80961A (en) | 1985-09-01 |
| BE903065A (fr) | 1986-02-14 |
| GR851988B (enrdf_load_stackoverflow) | 1985-12-10 |
| SE8503771D0 (sv) | 1985-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5091106B2 (ja) | 真性糖尿病の治療のためのロフルミラスト | |
| KR100544244B1 (ko) | 대사 장애, 특히 당뇨병 또는 당뇨병 관련 질환 또는증상의 치료 방법 | |
| EP1743655B1 (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| DE69729587T2 (de) | Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid | |
| EP3132792B1 (en) | Composition and methods for increasing insulin sensitivity | |
| EP0687472A2 (en) | Potentiation of drug response by a serotonin 1A receptor antagonist | |
| JP2015205909A (ja) | 組合せ | |
| KR20010032906A (ko) | 고위험의 내당력 장애를 치료하기 위한 알파-글루코시다제억제제의 용도 | |
| JP2008526733A (ja) | 糖尿病治療剤の経口投与用徐放性複合製剤及びその製造方法 | |
| JP2004508311A (ja) | 頭痛、片頭痛、悪心及び嘔吐用の医薬組成物 | |
| NZ506020A (en) | Use of pharmaceutical combinations containing tramadol and an antiemetic | |
| NL8502178A (nl) | Nieuwe farmaceutische preparaten. | |
| US8106081B2 (en) | Combination of organic compounds useful for treating diabetes | |
| JP4695326B2 (ja) | 鼻炎用医薬組成物 | |
| JPS6157516A (ja) | 新規医薬製剤 | |
| TW202521113A (zh) | 類風濕性關節炎治療藥 | |
| JPH05229944A (ja) | モノアミノオキシダーゼｂ阻害因子 | |
| HK1102405B (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| JPS59184124A (ja) | 腎不全、糖尿病及び糖尿病性腎症におけるエネルギー代謝改善剤 | |
| HK1108359B (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| HK1171663A (en) | Roflumilast for treatment of diabeties mellitus | |
| HK1102422B (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| HK1102424B (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| HK1013797A (en) | Potentiation of drug response by a serotonin 1a receptor antagonist | |
| HK1137345A (en) | Combination treatment for diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |